Aug. 12 at 12:39 PM
$CMPS $DFTX $HELP $ATAI Question and answer at the Canaccord Genuity’s conference directed at
$CMPS
Question -
So I'd be doing a disservice to your efforts if I didn't mention that you also have a program in PTSD.
How excited are you about that? And then this is a bigger picture question, which we can end with. You know, there's lots of the markets are large here, right? We appreciate that. We also appreciate that patients respond differently to different products. So given those variables, what do you think your key differentiator could be for comp 360 versus other psychedelic therapeutics that may also be approved and be on the market?
Start PTSD. Sure. Yeah. How excited are we about PTSD?
Answer -
Like jumping up and down, excited. Yes.
This, this is a huge unmet need. You know, we talk about the 4 million patients living with TRD who are underserved PTSD. There are 13 million adults in the US with PTSD.
Continued below.
